A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Rapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists in two distinct multiprotein complexes, mTORC1 and mTORC2...
Main Authors: | Hao Zhang, Dror Berel, Yanping Wang, Ping Li, Neil A Bhowmick, Robert A Figlin, Hyung L Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3551765?pdf=render |
Similar Items
-
Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
by: Haiyang Tang, PhD, et al.
Published: (2018-12-01) -
mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
by: Xiaolei Ding, et al.
Published: (2016-10-01) -
mTORC1 and mTORC2 differentially promote natural killer cell development
by: Chao Yang, et al.
Published: (2018-05-01) -
mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
by: Jin Young Yang, et al.
Published: (2019-06-01) -
LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
by: Marcelle C. Ribeiro, et al.
Published: (2018-07-01)